A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Official Title

Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

Summary:

This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumour activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.

Trial Description

Primary Outcome:

  • Percentage of patients who experience complete response, partial response, or stable disease
Secondary Outcome:
  • Adverse events based on frequency and proportion of total patients, by system organ class and preferred term.
  • Percentage of patients achieving either a complete or partial tumour response.
  • Interval between the date of randomization and the earliest date of disease progression or death due to any cause
  • Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.
Trametinib is a drug that works by binding to and blocking certain proteins called mitogen-activated protein kinase kinase (MEK) 1 and MEK2 from working. MEK1 and MEK2 are important proteins that contribute to the growth of cancer cells. GSK2256098 is a drug that blocks a protein called focal adhesion kinase-1 (FAK) which is an important protein that contribute to the growth of cancer cells.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society